International Oncology Network - Cancer & Hematology News

All Blog Posts Tagged 'Factor' (5)

Study Evaluating Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Patients with Severe Hemophilia B Starts Enrolling Patients

Earlier today the first patient has been enrolled in the pivotal pediatric phase III study to evaluate the safety, efficacy and pharmacokinetics of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP) in previously treated children (up to age 11 years). The study site for this first enrollment is the Czech Republic.

Hemophilia is an inherited bleeding disorder characterized by prolonged or spontaneous bleeding, especially into the muscles…

Continue

Added by Peter Hofland, PhD on January 31, 2013 at 8:30pm — No Comments

Researchers Discovers Genetic Risk Factor for Skin, Prostate and Brain Cancers

Scientists at deCODE Genetics, a specialist company focused on analyzing and understanding the human genome, and academic collaborators from Iceland, The Netherlands, Spain, Denmark, Germany, Sweden, the USA, the UK and Romania today report the discovery of a variant in the sequence of the human genome associated with risk of developing basal cell carcinoma of the skin (BCC), as well as prostate cancer and glioma, the most serious… Continue

Added by Peter Hofland, PhD on September 25, 2011 at 10:30am — No Comments

Rivaroxaban Significantly Reduces the Risk of Recurrent Venous Thromboembolism

Venous thromboembolism (VTE), a condition in which a blood vessel is blocked by a clot, is a common and potentially life-threatening disorder. In the United States, there are more than 200,000 new cases of VTE that occur annually. Treatment for acute VTE typically consists of an anticoagulant, such as a vitamin K inhibitor, for a period of six to 12… Continue

Added by Peter Hofland, PhD on December 6, 2009 at 11:30pm — No Comments

DECISION trial Evaluates Sorafenib in Patients with Non-Responsive Thyroid Cancer

Earlier this month recruitment has begun to enroll patients in an international Phase III trial to evaluate sorafenib (Nexavar®) tablets for the treatment of patients with radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer (papillary, follicular and Hurthle cell). The study is scheduled to start later this month at sites in the United States, Europe, Asia, and Japan. The study is schedules to complete in November 2011.

Thyroid… Continue

Added by Peter Hofland, PhD on October 23, 2009 at 2:08pm — No Comments

XL184 Shows Substantial Activity in Patients with Previously Treated Glioblastoma Multiforme and Medullary Thyroid Cancer

Results from the ongoing phase II trial of XL184 demonstrates substantial activity in patients with previously treated progressive or recurrent glioblastoma multiforme (study XL184-201). Data of the ongoing trial was presented during the 45th annual meeting of the American Society of Clinical Oncology (ASCO). XL184 has exhibited dose-dependent tumor growth inhibition and tumor regression in a variety of tumor models, including breast cancer, colon cancer, medullary thyroid cancer ,… Continue

Added by Peter Hofland, PhD on June 29, 2009 at 9:00am — No Comments